Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN69,8269,981,63
Msft1,13
Nokia4,2594,27954,41
IBM-1,99
Daimler AG73,373,330,92
PFE1,00
08.05.2021 1:38:06
Indexy online
AD Index online
select
AD Index online
 

  • 07.05.2021 22:00:00
Nektar Therap (NKTR.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
20,10 8,53 1,58 2 903 810
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 08.05.2021
Popis společnosti
Obecné informace
Název společnostiNektar Therapeutics
TickerNKTR
Kmenové akcie:Ordinary Shares
RICNKTR.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky31.03.2021
Počet zaměstnanců k 31.12.2020 718
Akcie v oběhu k 12.04.2021 182 296 922
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
Ulice455 Mission Bay Blvd S
MěstoSAN FRANCISCO
PSČ94158-2158
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon14 154 825 300
Fax13026555049

Business Summary: Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
Financial Summary: BRIEF: For the three months ended 31 March 2021, NektarTherapeutics revenues decreased 53% to $23.6M. Net lossdecreased 11% to $123M. Revenues reflect License,collaboration and other decrease of 100% to $54K, Royaltyrevenue decrease from $9.7M to $0K. Lower net loss reflectsInterest expense decrease from $6.2M (expense) to $0K.Basic Earnings per Share excluding Extraordinary Itemsincreased from -$0.78 to -$0.68.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBusiness Services
MGSECTORServices
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 08.05.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardRobert Chess6308.01.2007
President, Chief Executive Officer, DirectorHoward Robin6714.02.200715.01.2007
Chief Financial Officer, Chief Operating Officer, Senior Vice PresidentGilbert Labrucherie4801.10.201902.04.2007
Senior Vice President - Finance, Chief Accounting OfficerJillian Thomsen54
Senior Vice President and Chief Commercial OfficerJohn Northcott4203.12.201903.12.2019
Interim Chief Medical Officer, Head of DevelopmentBrian Kotzin-05.01.202105.01.2021
Chief Research and Development OfficerJonathan Zalevsky4501.10.201901.10.2019